These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7729310)

  • 1. Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose.
    Hegele RA; Connelly PW; Palmason C; Jenkins DJ; Wolever TM
    Diabetes Care; 1995 Feb; 18(2):272-3. PubMed ID: 7729310
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J; Spengler M
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral antidiabetics: acarbose].
    Taurand S
    Soins; 1996 May; (606):61-2. PubMed ID: 8717785
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy and safety of acarbose treatment of NIDDM].
    Wainstein J; Jedwab M
    Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.
    Rodier M; Richard JL; Monnier L; Mirouze J
    Diabete Metab; 1988; 14(1):12-4. PubMed ID: 3292303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
    Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
    Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of acarbose for treating diabetic patients].
    Balabolkin MI; Dedov II; Mkrtumian AM; Ametov AS; Kakhnovskiĭ IM; Chazova TE; Koroleva TS; Kochergina II; Matveeva LS
    Ter Arkh; 1994; 66(10):20-1. PubMed ID: 7863437
    [No Abstract]   [Full Text] [Related]  

  • 14. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
    Spengler M; Cagatay M
    Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose: in search for its real indications in current medical practice.
    Lerman I; Gómez Perez FJ; Aguilar-Salinas CA; Rodrigo JA
    Diabetes Care; 1996 Jan; 19(1):94-5. PubMed ID: 8720547
    [No Abstract]   [Full Text] [Related]  

  • 17. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
    Holman RR; Cull CA; Turner RC
    Diabetes Care; 1999 Jun; 22(6):960-4. PubMed ID: 10372249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.
    Josse RG
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S167-72. PubMed ID: 8529510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.